BioCardia, Inc.
BCDA
Rank in Stocks
#27766
BioCardia, Inc. is a pioneering clinical-stage company dedicated to... BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardia also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.
Share Price
$0.9026
Last synced: 2026-11-09
Market Cap
$13.66M
Change (1 day)
6.19%
Change (1 year)
-32.14%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade BioCardia, Inc. (BCDA)
Category
Healthcare
Operating Margin for BioCardia, Inc. (BCDA)
Operating Margin as of November 2026 TTM: 0.00%
According to BioCardia, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for BioCardia, Inc. from 2001 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | -100.00% |
| 2024 | -13,794.83% | 465.11% |
| 2023 | -2,441.09% | 177.32% |
| 2022 | -880.25% | -29.26% |
| 2021 | -1,244.33% | -88.38% |
| 2020 | -10,709.66% | 434.99% |
| 2019 | -2,001.83% | -11.28% |
| 2018 | -2,256.32% | -12.88% |
| 2017 | -2,589.77% | 96.07% |
| 2016 | -1,320.83% | -2,240.73% |
| 2015 | 61.70% | 14.05% |
| 2014 | 54.10% | 1,510.12% |
| 2013 | 3.36% | -100.61% |
| 2012 | -546.77% | -89.38% |
| 2011 | -5,150.00% | 0.00% |
| 2010 | 0.00% | -100.00% |
| 2009 | -272.98% | -38.54% |
| 2008 | -444.16% | 0.00% |
| 2007 | 0.00% | 0.00% |
| 2006 | 0.00% | 0.00% |
| 2005 | 0.00% | -100.00% |
| 2004 | -20.75% | 67.88% |
| 2003 | -12.36% | -57.58% |
| 2002 | -29.14% | -44.18% |
| 2001 | -52.20% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about BioCardia, Inc.'s operating margin
What was BioCardia, Inc.'s operating margin in 2025?
In 2025, BioCardia, Inc.'s operating margin was 0.00%, compared with -13,794.83% in 2024.
How has BioCardia, Inc.'s operating margin changed since 2020?
From 2020 to 2025, BioCardia, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2024 (-13,794.83%).
How does BioCardia, Inc.'s operating margin compare with similar companies?
BioCardia, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.